Nitrofurazone

Summary

Nitrofurazone (CHEMBL869) is an approved small molecule (ATC B05CA03); indicated across 5 conditions including trypanosomiasis and leishmaniasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05CA03 (+5 more)
• Indications: 5 conditions
• Chemistry: 198.14 Da · C6H6N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL869
Name	Nitrofurazone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5447130
ATC	B05CA03, P01CC02, S02AA02, D09AA03, D08AF01, S01AX04
Molecular formula	C6H6N4O4
Molecular weight	198.14
InChIKey	IAIWVQXQOWNYOU-FPYGCLRLSA-N

SMILES: C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N

IUPAC name: [(E)-(5-nitrofuran-2-yl)methylideneamino]urea

Also known as: Actin-n, Furacin, Furacine, Nitrofural, Nitrofurazone, NSC-1602, NSC-2100, nitrofurazone, SID17389801, SID26747226, SID26752739, SID56463220

Parent form; salt/anhydrous children: CHEMBL1204113

Patent coverage: 4,978 distinct patent families (13,461 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, Snake venom metalloproteinase BaP1, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1, Cellular tumor antigen p53, NAD(+) hydrolase SARM1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.95	Potency	11.2	nM	CHEMBL_ACT_3653160
P51450	5.2	Potency	6310	nM	CHEMBL_ACT_4089235

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
trypanosomiasis	4	MONDO:0000940	DOID:10113
leishmaniasis	4	MONDO:0011989	EFO:0005044
eye infectious disorder	4	MONDO:0043885	EFO:1001888
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazid	CPIC	G6PD

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).